代谢功能障碍相关脂肪性肝病高危人群的监测及管理

摘要/Abstract

摘要： 随着抗病毒治疗药物普及和生活水平日益提高,代谢功能障碍相关脂肪性肝病(MASLD)日渐成为影响全球慢性肝病患者生存的主要疾病之一。与非酒精性脂肪性肝病相比,MASLD诊断更具有代谢指标“阳性”“非歧视”等优势,提高了医患对此疾病的认知及重视。MASLD发病基础为胰岛素抵抗,因此高危人群主要集中于肥胖、2型糖尿病及瘦型代谢指标异常的人群。该人群筛查时首选简单、低成本的超声或肝脏瞬时弹性成像检查,可结合代谢指标综合制定治疗方案。个体化方案制定以饮食减重为主,无相对禁忌证的患者可适当增加锻炼,具有血糖异常、血脂异常或心脑血管疾病的患者可配合相应有效药物进行治疗。病态肥胖无法自行减重或药物治疗效果较差的患者可评估进行外科减重治疗。

李俊缨, 陈金军. 代谢功能障碍相关脂肪性肝病高危人群的监测及管理[J]. 肝脏, 2026, 31(8): 1192-1195.

/ 推荐

参考文献

[1] Cheah M C C, Crane H, George J. Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis[J]. Hepatol Int, 2025, 19(3):607-618.
[2] Cheng H N, Daniel Q H, Mindie H N. Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: prevalence, outcomes and implications of a change in name[J]. Clin Mol Hepatol, 2022, 28(4):790-801.
[3] Alexander H Y, Monica A T, Federica T, et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA[J]. Gut, 2024, 73(12):2045-2053.
[4] Veeral A, Sandra C, Kaleb T, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes[J]. J Hepatol, 2023, 78(3):471-478.
[5] Marti-Aguado D, Calleja J L, Vilar-Gomez E, et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease[J]. J Hepatol, 2024, 81(6):930-940.
[6] Luis A D, Juan P A, Alexandre L, et al. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol,2023,20(12):764-783.
[7] David M A, Ana C S, Ramon B, et al. Cigarette smoking and liver diseases[J]. J Hepatol, 2022, 77(1):191-205.
[8] Alessandro C, Mahnoosh O, Oveis J, et al. Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women[J]. Nat Med, 2023, 29(10):2643-2655.
[9] Stephen A H, Pierre B, Cynthia D G, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024, 390(6):497-509.
[10] Alina M A, Ray K, Patrizia C, et al. Population perspectives on benefits and harms of screening for metabolic dysfunction-associated steatotic liver disease[J]. Hepatology, 2026, 83(2):362-373.
[11] EASL, EASD, EASO, EASL. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)[J]. J Hepatol, 2024, 81(3):492-542.
[12] Chul-Min L, Eileen L Y, Atsushi N, et al. A reappraisal of the diagnostic performance of B-mode ultrasonography for mild liver steatosis[J]. Am J Gastroenterol, 2023, 118(5):840-847.
[13] Cyrielle C, Mosab H A, Phirum N, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis[J]. Hepatology, 2018, 67(4):1348-1359.
[14] Philip N N, Magali S, Jonathan J D, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5(4):362-373.
[15] Mazen N, Emily T, Jeffrey A G, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis[J]. J Hepatol, 2022, 76(4):781-787.
[16] Stuart M, Stephen F S, Elsbeth H, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease[J]. Gut, 2010, 59(9):1265-1269.
[17] Jia-Xu L, Javier A, Hao N, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023, 79(3):592-604.
[18] Zobair M Y, Kathleen E C, Joseph K L, et al. AGA Clinical Practice Update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2021, 160(3):912-918.
[19] Estruch R. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts[J]. N Engl J Med, 2018, 379(14):1388.
[20] Chanthawat P, Kiera R, Sajesh K V, et al. Intermittent fasting and obesity-related health outcomes: an umbrella review of meta-analyses of randomized clinical trials[J]. JAMA Netw Open, 2021, 4(12):e2139558.
[21] Guo L X, Xi Y, Jin W B, et al. A 5∶2 intermittent fasting meal replacement diet and glycemic control for adults with diabetes: the EARLY randomized clinical trial[J]. JAMA Netw Open, 2024, 7(6):e2416786.
[22] Sun X Y, Li F, Yan H M, et al. Intermittent compared with continuous calorie restriction for treatment of metabolic dysfunction-associated steatotic liver disease: a randomized clinical trial[J]. Am J Clin Nutr, 2025, 121(1):158-166.
[23] Naparat S, Supawan B. Effect of intermittent fasting 16∶8 and 14∶10 compared with control-group on weight reduction and metabolic outcomes in obesity with type 2 diabetes patients: a randomized controlled trial[J]. J Diabetes Investig, 2024, 15(9):1297-1305.
[24] Dimitrios A K, Nerys M A, Kate E T, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. JAMA Intern Med, 2019, 179(9):1262-1271.
[25] DiBattista J V, Lok A S, Chen V L, et al. Long-term weight changes are associated with initial weight changes after nonalcoholic fatty liver disease diagnosis[J]. Hepatol Commun, 2023, 7(3):e0044.
[26] Keating S E, Sabag A, Hallsworth K, et al. Exercise in the management of metabolic-associated fatty liver disease (MAFLD) in adults: A position statement from exercise and sport science Australia[J]. Sports Med, 2023, 53(12):2347-2371.
[27] Harrison S A, Taub R, Neff G W, et al. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial[J]. Nat Med, 2023, 29(11):2919-2928.
[28] Karim G, Bansal MB. Resmetirom: an orally administered, small-molecule, liver-directed, β-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. touchREV Endocrinol, 2023, 19(1):60-70.
[29] Newsome P N, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis[J]. N Engl J Med, 2021, 384(12):1113-1124.
[30] Zhou X D, Kim S U, Yip T C, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease[J]. Gut, 2024, 73(11):1883-1892.
[31] Simon T G, Wilechansky R M, Stoyanova S, et al. Aspirin for metabolic dysfunction-associated steatotic liver disease without cirrhosis: a randomized clinical trial[J]. JAMA, 2024, 331(11):920-929.
[32] Mohamed I E, You L, John F P, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease[J]. JAMA Netw Open, 2022, 5(10):e2235003.